8-(3-aminobenzyloxy)quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-(3-aminobenzyloxy)quinoline
• 英文别名: 3-(Quinolin-8-yloxymethyl)aniline
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: QACIULJFKRXDKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-(3-aminobenzyloxy)quinoline 生成 4-chloro-N-[3-(quinolin-8-yloxymethyl)phenyl]benzenesulfonamide
  参考文献：
  名称：

  MOHRS, KLAUS;PERZBORN, ELISABETH;SEUTER, FRIEDEL;FRUCHTMANN, ROMANIS;KOHL+

  摘要：

  DOI：
• 作为产物：
  描述：

  8-(3-nitrobenzyloxy)quinoline 生成 8-(3-aminobenzyloxy)quinoline
  参考文献：
  名称：

  MOHRS, KLAUS;PERZBORN, ELISABETH;SEUTER, FRIEDEL;FRUCHTMANN, ROMANIS;KOHL+

  摘要：

  DOI：

文献信息

• Substituierte Phenylsulfonamide
  申请人：BAYER AG

  公开号：EP0261539A2

  公开（公告）日：1988-03-30

  Neue substituierte Phenylsulfonamide können durch Umsetzung von entsprechenden Aminen mit Sulfonhalogeniden hergestellt werden. Die neuen Verbindungen können als Wirkstoffe zur Hemmung von enzymatischen Reaktionen und zur Hemmung der Thrombozytenaggregationen eingesetzt werden.

  通过将相应的胺与磺酰卤反应，可以生成新的取代苯基磺酰胺。 新化合物可用作抑制酶反应和抑制血小板聚集的活性物质。
• Method of preparing a composition containing hygromycin A and epi-hygromycin
  申请人：Pfizer Products Inc.

  公开号：EP1369490A1

  公开（公告）日：2003-12-10

  A method of preparing a composition containing hygromycin A and epi-hygromycin, wherein the ratio of hygromycin A to epi-hygromycin is at least 10:1, which comprises fermenting Streptomyces hygroscopicus in media having a pH less than 6.9 at a temeperature ranging from 25°C to 35°C.

  一种制备含百日咳霉素 A 和表-百日咳霉素的组合物的方法，其中百日咳霉素 A 与表-百日咳霉素的比例至少为 10:1，该方法包括在 pH 值小于 6.9 的培养基中，在 25°C 至 35°C 的温度范围内发酵吸湿链霉菌。
• Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)- N -phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors
  作者：Lingling Yang、Xiaobo Ma、Chen Yuan、Yanying He、Ling Li、Sha Fang、Wei Xia、Tao He、Shan Qian、Zhihong Xu、Guobo Li、Zhouyu Wang

  DOI：10.1016/j.ejmech.2017.04.010

  日期：2017.7

  Human sirtuin 2 (SIRT2) plays pivotal roles in multiple biological processes such as cell cycle regulation, autophagy, immune and inflammatory responses. Dysregulation of SIRT2 was considered as a main aspect contributing to several human diseases, including cancer. Development of new potent and selective SIRT2 inhibitors is currently desirable, which may provide a new strategy for treatment of related diseases. Herein, a structure-based optimization approach led to new 2-((4,6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as SIRT2 inhibitors. SAR analyses with new synthesized derivatives revealed a number of new potent SIRT2 inhibitors, among which 28e is the most potent inhibitor with an IC50 value of 42 nM. The selectivity analyses found that 28e has a very good selectivity to SIRT2 over SIRT1 and SIRT3. In cellular assays, 28e showed a potent ability to inhibit human breast cancer cell line MCF-7 and increase the acetylation of alpha-tubulin in a dose-dependent manner. This study will aid further efforts to develop highly potent and selective SIRT2 inhibitors for the treatment of cancer and other related diseases. (C) 2017 Elsevier Masson SAS. All rights reserved.
• HYGROMYCIN A DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1075483B1

  公开（公告）日：2003-12-03
• 2"-DEOXY HYGROMYCIN DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1077984B1

  公开（公告）日：2003-06-18